UMMS Affiliation

Horae Gene Therapy Center; Department of Microbiology and Physiological Systems; Li Weibo Institute for Rare Diseases Research

Publication Date

2020-10-06

Document Type

Article

Disciplines

Immunology of Infectious Disease | Immunopathology | Immunoprophylaxis and Therapy | Immunotherapy | Infectious Disease | International Public Health | Microbiology | Therapeutics | Virus Diseases

Abstract

A recent report by Yang et al. published in Nature reported a recombinant vaccine utilizing recombinant receptor-binding domain (RBD) of SARS-CoV-2 Spike Protein.This vaccine candidate successfully induced potent functional antibody responses in the immunized mice, rabbits, and non-human primates. The study highlights the critical role of the immunogenicity of the RBD domain upon SARS-CoV-2 infection and the alternate vaccine designs that could serve as effective prophylactics against the pandemic.

Keywords

COVID-19, pandemic, vaccine, recombinant receptor-binding domain, RBD, SARS-CoV-2 Spike Protein

Rights and Permissions

Copyright © The Author(s) 2020. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

DOI of Published Version

10.1038/s41392-020-00317-1

Source

Muhuri M, Gao G. Is smaller better? Vaccine targeting recombinant receptor-binding domain might hold the key for mass production of effective prophylactics to fight the COVID-19 pandemic. Signal Transduct Target Ther. 2020 Oct 6;5(1):222. doi: 10.1038/s41392-020-00317-1. PMID: 33024086; PMCID: PMC7537771. Link to article on publisher's site

Journal/Book/Conference Title

Signal transduction and targeted therapy

Related Resources

Link to Article in PubMed

PubMed ID

33024086

Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

Share

COinS